Dhondt J L, Farriaux J P, Lebrun T, Sailly J C
Centre régional de dépistage des maladies métaboliques de l'enfant, Faculté de Médecine, Lille, France.
Pediatrie. 1988;43(4):345-8.
The medical importance of an early screening for phenylketonuria (PKU) and congenital hypothyroidism (CH) has been recognized for a long time. However, only rare cost-benefit analysis have been reported. A comparison between the cost of identification and care of PKU and CH patients and the expenditure for the care of untreated retarded patients has been established on the basis of the activity of the Nord-Pas-de-Calais regional screening centre and of patient's families interviews. The present analysis yields a cost-benefit ratio of 6.5 for PKU and 12.2 for CH prophylaxis. However cost-benefit varies depending on the economical partner: patient's family, Social Security or Administration. The present model may also be useful cost-benefit calculation when new tests will be planned to be introduced in the national neonatal screening programme.
长期以来，人们已经认识到早期筛查苯丙酮尿症（PKU）和先天性甲状腺功能减退症（CH）的医学重要性。然而，仅有少数关于成本效益分析的报道。基于加来海峡大区筛查中心的活动以及对患者家庭的访谈，已对苯丙酮尿症和先天性甲状腺功能减退症患者的识别与护理成本以及未治疗的智力迟钝患者的护理费用进行了比较。目前的分析得出苯丙酮尿症的成本效益比为6.5，先天性甲状腺功能减退症预防的成本效益比为12.2。然而，成本效益因经济合作伙伴而异：患者家庭、社会保障部门或政府部门。当计划在国家新生儿筛查项目中引入新检测时，当前模型也可能有助于成本效益计算。
